Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings. Materials and methods. A non-interventional non-comparative observational stud...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marina S. Lebedkina, Daria S. Fomina, Zinaida Y. Mutovina, Ulyana A. Mаrkina, Pavel O. Bogomolov, Vladimir P. Chulanov, Mariana A. Lysenko, Ekaterina I. Alexeeva
Format:	Artigo
Idioma:	Russo
Publicat:	"Consilium Medicum" Publishing house 2023-08-01
Col·lecció:	Терапевтический архив
Matèries:	covid-19 casirivimab/imdevimab efficiency safety
Accés en línia:	https://ter-arkhiv.ru/0040-3660/article/viewFile/516486/pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!